U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.52%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.36%)
     
  • BTC-USD

    49,684.52
    +981.48 (+2.02%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

French drugmaker Cellectis in sale talks -FT

May 28 (Reuters) - French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc, the Financial Times reported citing people familiar with the matter.

Although no outcome is certain of the talks, Pfizer, which already owns 9.47 percent of Cellectis, has approached it for a takeover, valuing it at 1.5 billion euros ($1.64 billion), FT said. (http://on.ft.com/1G3Z7hP)

Cellectis and Pfizer could not be immediately reached for comment.

In March, Cellectis listed itself on the Nasdaq raising $228 million through the sale of American Depository shares.

Cellectis, which works in the hot area of cancer immunotherapy, signed a deal with Pfizer last year to develop immunotherapy drugs.

($1 = 0.9135 euros) (Reporting by Ankush Sharma in Bangalore)